Skip to content

Zevra Therapeutics, Inc. ZVRA Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
XER
Xeris Biopharma Holdings, Inc.XERS
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
Theravance Biopharma logo
Theravance BiopharmaTBPH
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s deferred tax assets and other non-current assets?
Zevra Therapeutics, Inc. (ZVRA) reported deferred tax assets and other non-current assets of $143K in Q1 2026.
How has Zevra Therapeutics, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Zevra Therapeutics, Inc.'s deferred tax assets and other non-current assets decreased by 51.2% year-over-year, from $293K to $143K.
What is the long-term trend for Zevra Therapeutics, Inc.'s deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s deferred tax assets and other non-current assets has grown at a -20.1% compound annual growth rate (CAGR), from $438K to $143K.